199 related articles for article (PubMed ID: 35069811)
1. Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials.
Zhao D; Luo MH; Pan JK; Zeng LF; Liang GH; Han YH; Liu J; Yang WY
Ther Adv Musculoskelet Dis; 2022; 14():1759720X211067639. PubMed ID: 35069811
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.
Chen J; Li J; Li R; Wang H; Yang J; Xu J; Zha Z
Pain Med; 2017 Feb; 18(2):374-385. PubMed ID: 28034979
[TBL] [Abstract][Full Text] [Related]
3. Safety of Low-Dose Tanezumab in the Treatment of Hip or Knee Osteoarthritis: A Systemic Review and Meta-analysis of Randomized Phase III Clinical Trials.
Yu Y; Lu ST; Sun JP; Zhou W
Pain Med; 2021 Mar; 22(3):585-595. PubMed ID: 33141224
[TBL] [Abstract][Full Text] [Related]
4. Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials.
Zhao D; Zeng LF; Liang GH; Pan JK; Luo MH; Han YH; Liu J; Yang WY
EFORT Open Rev; 2022 Jul; 7(7):470-480. PubMed ID: 35900204
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
[TBL] [Abstract][Full Text] [Related]
6. Relative Efficacy and Safety of Tanezumab for Osteoarthritis: A Systematic Review and Meta-analysis of Randomized-Controlled Trials.
Zhang B; Tian X; Qu Z; Liu J; Yang L
Clin J Pain; 2021 Dec; 37(12):914-924. PubMed ID: 34608021
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials.
Fan ZR; Ma JX; Wang Y; Chen HT; Lang S; Ma XL
Clin Rheumatol; 2021 Jun; 40(6):2155-2165. PubMed ID: 33159281
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.
Schnitzer TJ; Marks JA
Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S8-17. PubMed ID: 25527221
[TBL] [Abstract][Full Text] [Related]
9. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.
Neogi T; Hunter DJ; Churchill M; Shirinsky I; White A; Guermazi A; Omata M; Fountaine RJ; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
Arthritis Res Ther; 2022 Mar; 24(1):78. PubMed ID: 35351194
[TBL] [Abstract][Full Text] [Related]
10. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
[TBL] [Abstract][Full Text] [Related]
11. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip.
Tive L; Bello AE; Radin D; Schnitzer TJ; Nguyen H; Brown MT; West CR
J Pain Res; 2019; 12():975-995. PubMed ID: 30936738
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
[TBL] [Abstract][Full Text] [Related]
13. Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis.
Kan SL; Li Y; Ning GZ; Yuan ZF; Chen LX; Bi MC; Sun JC; Feng SQ
PLoS One; 2016; 11(6):e0157105. PubMed ID: 27294371
[TBL] [Abstract][Full Text] [Related]
14. Chondroitin for osteoarthritis.
Singh JA; Noorbaloochi S; MacDonald R; Maxwell LJ
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD005614. PubMed ID: 25629804
[TBL] [Abstract][Full Text] [Related]
15. Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(10):1-66. PubMed ID: 23074461
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen.
Ekman EF; Gimbel JS; Bello AE; Smith MD; Keller DS; Annis KM; Brown MT; West CR; Verburg KM
J Rheumatol; 2014 Nov; 41(11):2249-59. PubMed ID: 25274899
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
[TBL] [Abstract][Full Text] [Related]
19. Paracetamol versus placebo for knee and hip osteoarthritis.
Leopoldino AO; Machado GC; Ferreira PH; Pinheiro MB; Day R; McLachlan AJ; Hunter DJ; Ferreira ML
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD013273. PubMed ID: 30801133
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Anti-Nerve Growth Factor Antibody Therapy for Hip and Knee Osteoarthritis: A Meta-analysis.
Gao Y; Hu Z; Huang Y; Liu W; Ren C
Orthop J Sports Med; 2022 Apr; 10(4):23259671221088590. PubMed ID: 35494494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
